Short Interest in Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) Rises By 29.8%

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) was the recipient of a significant growth in short interest in January. As of January 30th, there was short interest totaling 85,580 shares, a growth of 29.8% from the January 15th total of 65,924 shares. Based on an average daily trading volume, of 69,840 shares, the short-interest ratio is presently 1.2 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 69,840 shares, the short-interest ratio is presently 1.2 days.

Sandoz Group Stock Up 0.0%

Shares of Sandoz Group stock opened at $85.73 on Monday. Sandoz Group has a 1 year low of $35.61 and a 1 year high of $86.80. The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62. The stock has a fifty day moving average price of $76.52 and a 200-day moving average price of $67.61.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, Sandoz Group currently has a consensus rating of “Strong Buy”.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.